Metabolic associated liver disease

被引:1
|
作者
Testino, Gianni [1 ,3 ]
Pellicano, Rinaldo [2 ]
机构
[1] Polyclin San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O, Genoa, Italy
[2] Molinette SGAS Hosp, Unit Gastroenterol, Turin, Italy
[3] Polyclin San martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O Padigl 10,Piazzale R Benzi 10, I-16132 Genoa, Italy
关键词
Alcohol drinking; Metabolic syndrome; Non-alcoholic fatty liver disease; Diabetes mellitus; type; 2; NONALCOHOLIC FATTY LIVER; ALCOHOL-USE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BLOOD-PRESSURE; FIBROSIS; RISK; IDENTIFICATION; PERFORMANCE; MANAGEMENT;
D O I
10.23736/S0031-0808.22.04730-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In real practice the patient with liver disease is often the carrier of multiple etiological factors such as metabolic syndrome (MS) and alcohol consumption (AC). Their copresence is often underestimated and AC is not adequately studied. Traditionally to diagnose non-alcoholic fatty liver disease (NAFLD), AC must not exceed 30 gr for men and 20 gr for women per day. This limit should still be reduced, especially in relation to the AC and fibrogenesis ratio and also frequent misestimation of AC or unrecognized MS may underestimate multi caused liver injury. AC is a contributing cause of MS and alcoholic and non-alcoholic liver disease have a substantially overlapping histopathological picture. Moreover, AC and MS are cause and contributing cause of extra-hepatic morbidity and mortality. It can be concluded that the possible simplification of terminology at metabolic associated liver disease (MALD) makes clinical activity more usable and immediate, facilitates better communication and cooperation between scientific societies and specialists who apparently deal with different medical sectors, facilitates early identification of related hepatic and extra-hepatic pathology, allows to "see the person in a unitary way," to create more streamlined care pathways, to reduce the hospitalization rate with relative cost-benefit advantage and to create unitary prevention and health promotion policies.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [41] Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects
    Moller, Soren
    Kimer, Nina
    Hove, Jens Dahlgaard
    Barlose, Mads
    Gluud, Lise Lotte
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2025,
  • [42] Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B
    Huang, Shang -Chin
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2148 - 2151
  • [43] Chronic hepatitis B with concurrent metabolic dys-function-associated fatty liver disease: Challenges and perspectives
    Huang, Shang -Chin
    Liu, Chun-Jen
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (02) : 320 - 331
  • [44] Albuminuria Is Associated with Hepatic Iron Load in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome
    Abbate, Manuela
    Montemayor, Sofia
    Mascaro, Catalina M.
    Casares, Miguel
    Gomez, Cristina
    Ugarriza, Lucia
    Tejada, Silvia
    Abete, Itziar
    Angeles Zulet, Maria
    Sureda, Antoni
    Alfredo Martinez, J.
    Tur, Josep A.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [45] Pathobiology of Metabolic-Associated Fatty Liver Disease
    Fouda, Sherouk
    Jeeyavudeen, Mohammed Sadiq
    Pappachan, Joseph M.
    Jayanthi, Venkataraman
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 405 - 416
  • [46] Total choline intake, liver fibrosis and the progression of metabolic dysfunction-associated steatotic liver disease: Results from 2017 to 2020 NHANES
    Taesuwan, Siraphat
    Kouvari, Matina
    McKune, Andrew J.
    Panagiotakos, Demosthenes B.
    Khemacheewakul, Julaluk
    Leksawasdi, Noppol
    Rachtanapun, Pornchai
    Naumovski, Nenad
    MATURITAS, 2025, 191
  • [47] Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease br
    Seo, Da Hea
    Suh, Young Ju
    Cho, Yongin
    Ahn, Seong Hee
    Seo, Seongha
    Hong, Seongbin
    Lee, Yong -ho
    Choi, Young Ju
    Lee, Eunjig
    Kim, So Hun
    DIABETES & METABOLISM JOURNAL, 2022, 46 (04) : 630 - 639
  • [48] Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
    Lim, Tae Seop
    Chun, Ho Soo
    Kim, Soon Sun
    Kim, Ja Kyung
    Lee, Minjong
    Cho, Hyo Jung
    Kim, Seung Up
    Cheong, Jae Youn
    GUT AND LIVER, 2023, 17 (04) : 610 - 619
  • [49] Combined effect of histological findings and diabetes mellitus on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease
    Shiomi, Akihito
    Miyake, Teruki
    Furukawa, Shinya
    Matsuura, Bunzo
    Yoshida, Osamu
    Watanabe, Takao
    Kanamoto, Ayumi
    Miyazaki, Masumi
    Nakaguchi, Hironobu
    Tokumoto, Yoshio
    Hirooka, Masashi
    Abe, Masanori
    Hiasa, Yoichi
    HEPATOLOGY RESEARCH, 2024, 54 (11) : 1016 - 1026
  • [50] Patterns of gastroenterology specialty referral for primary care patients with metabolic dysfunction-associated steatotic liver disease
    Bobo, John F. G.
    Keith, Brad A.
    Marsden, Justin
    Zhang, Jingwen
    Schreiner, Andrew D.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 368 (05) : 455 - 461